Physician profile
Li Li
NPI 1710959523
$12,577.13
in general payments reported to CMS, 2019-2025
41 companies · $406 in 2025
The $406 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $2,171 · 2021: $2,508 · 2022: $2,252 · 2023: $2,856 · 2024: $217 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397 · Travel and Lodging: $1,070 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.02 |
| Travel and Lodging | $1,069.68 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,692.29 | 2019-2023 | |
| Glaxosmithkline, LLC. | $1,750.19 | 2019-2025 | Trelegy Ellipta, Nucala |
| Abbvie INC. | $1,327.80 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $731.12 | 2021-2025 | |
| Amarin Pharma, INC. | $688.82 | 2019-2023 | |
| Allergan, INC. | $579.26 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $431.28 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $416.18 | 2019-2023 | |
| Lilly USA, LLC | $395.62 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $395.00 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals Lp | $389.31 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $357.59 | 2019-2025 | |
| Novo Nordisk INC | $311.92 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $297.16 | 2020-2025 | Caplyta |
| Astellas Pharma US INC | $257.73 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.